Aprea Therapeutics, Inc.
APRE
$1.40
-$0.05-3.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 841.00K | 1.28M | 1.50M | 1.31M | 1.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 841.00K | 1.28M | 1.50M | 1.31M | 1.28M |
| Cost of Revenue | 9.60M | 10.25M | 9.36M | 9.05M | 8.33M |
| Gross Profit | -8.76M | -8.96M | -7.86M | -7.74M | -7.05M |
| SG&A Expenses | 6.04M | 6.29M | 6.46M | 7.03M | 7.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.64M | 16.54M | 15.82M | 16.08M | 15.47M |
| Operating Income | -14.80M | -15.26M | -14.32M | -14.77M | -14.19M |
| Income Before Tax | -13.85M | -14.08M | -12.96M | -13.51M | -12.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.85 | -14.08 | -12.96 | -13.51 | -12.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.85M | -14.08M | -12.96M | -13.51M | -12.93M |
| EBIT | -14.80M | -15.26M | -14.32M | -14.77M | -14.19M |
| EBITDA | -14.77M | -15.23M | -14.30M | -14.75M | -14.18M |
| EPS Basic | -2.31 | -2.36 | -2.38 | -2.81 | -3.03 |
| Normalized Basic EPS | -1.44 | -1.48 | -1.49 | -1.76 | -1.90 |
| EPS Diluted | -2.31 | -2.36 | -2.38 | -2.81 | -3.03 |
| Normalized Diluted EPS | -1.44 | -1.48 | -1.49 | -1.76 | -1.90 |
| Average Basic Shares Outstanding | 23.97M | 23.83M | 22.03M | 19.81M | 17.61M |
| Average Diluted Shares Outstanding | 23.97M | 23.83M | 22.03M | 19.81M | 17.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |